Skip to content

Testing the Helpfulness of 2 Decision Aids for Prostate Cancer

Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00432601
Enrollment
1028
Registered
2007-02-08
Start date
2008-08-31
Completion date
2012-09-30
Last updated
2016-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

decision aid, prostate cancer, patient-physician communication, decision making, literacy

Brief summary

The purpose of this study is to test different methods for communicating information about prostate cancer treatment to men. The investigators are studying how best to present information so men can make informed decisions about what prostate cancer treatment to undergo.

Detailed description

Background/Rationale: Prostate cancer is the second leading cause of cancer related death among men in the United States, and accounts for 29% of all cancers diagnosed in men. Furthermore, approximately one in six men will be diagnosed with prostate cancer in their lifetime. Thus, 17% of male Veterans will be asked to make a decision about the treatment of their prostate cancer. The burden of this disease is further magnified when one considers that most patients will live for years following their diagnosis and with any adverse effects of therapy. Given that there have been no clinical trials showing that any prostate cancer treatment produces an increased likelihood of survival; men are asked to actively participate in treatment decisions. Previous research has revealed that men are often uninformed about their prostate cancer, particularly African American men and men with lower educational attainment. Thus, it is critical to develop and test decision aids that can help all men (especially men with low literacy skills) make an informed decision. Objective(s): The goal of the study is to compare the impact of a plain language decision aid (DA) to a conventional DA on prostate cancer patients' decision making experience and communication with their physician. Methods: This study is a randomized controlled trial. Men undergoing a prostate biopsy will be recruited at the time of biopsy and complete a baseline interview (at pre-biopsy or biopsy appointment). Those patients diagnosed with localized prostate cancer will complete two additional interviews: at physician visit (diagnosis), and 7-10 days following physician visit (phone survey). The treatment discussion between patients and their physician will be audio recorded. Major characteristics: All men, without a prior history of prostate cancer, undergoing a prostate biopsy will be screened for eligibility and enrolled by the study coordinator. Additional inclusion criteria include ability to speak English, provide informed consent, and have a PSA \< 20. Physicians can refuse to allow a patient participate in the study at the time of biopsy. Men will be recruited from 4 VA hospitals (Ann Arbor, Durham, Pittsburgh, and San Francisco) and randomized to receive one of two decision aid booklets (plain language vs. conventional). Major variables and source(s) of data: All survey data will be collected from either face-to-face or phone interviews. The surveys include measures of literacy, numeracy, anxiety, preference for shared decision making, knowledge, treatment preferences, risk perceptions, perception of patient-physician communication, and confidence and satisfaction with the decision making process. All survey questions were read aloud and responses recorded. Status: Recruitment began in September 2008 and concluded in May of 2012. 1552 men were approached to participate in the study with 1028 agreeing. 1023 completed the Time 1 interview. Of the 334 subjects eligible to continue with study activities, 285 subjects completed the Time 2 interview (biopsy results visit), and 244 completed the Time 3 phone interview.

Interventions

BEHAVIORALtype of decision aid

We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

Men undergoing a prostate cancer biopsy at Ann Arbor, Durham, San Francisco, or Pittsburgh VAs. Additional inclusion criteria includes ability to speak English, provide informed consent, and have a PSA \< 20.

Exclusion criteria

Prior history of prostate cancer

Design outcomes

Primary

MeasureTime frameDescription
KnowledgeResults visit (Time 2 - approximately 7-10 days after Time 1)Questions addressed the survival benefit and side effects associated with treatment options for localized prostate cancer.

Countries

United States

Participant flow

Participants by arm

ArmCount
Arm 1
Patients will receive Michigan Cancer Consortium decision aid. type of decision aid: We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
510
Arm 2
Patients will receive National Comprehensive Cancer Network decision aid. type of decision aid: We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
512
Total1,022

Baseline characteristics

CharacteristicArm 1Arm 2Total
Age, Continuous63.41 years
STANDARD_DEVIATION 5.86
63.14 years
STANDARD_DEVIATION 6.02
63.28 years
STANDARD_DEVIATION 5.94
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
510 Participants512 Participants1022 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
1 / 5100 / 512
serious
Total, serious adverse events
0 / 5100 / 512

Outcome results

Primary

Knowledge

Questions addressed the survival benefit and side effects associated with treatment options for localized prostate cancer.

Time frame: Results visit (Time 2 - approximately 7-10 days after Time 1)

ArmMeasureValue (MEAN)Dispersion
Arm 1 - MCCKnowledge53 percentage correct on a 12 item scaleStandard Error 0.03
Arm 2 - NCCNKnowledge48 percentage correct on a 12 item scaleStandard Error 0.03

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026